Table 2.
Patient cohorts by country with duration of IVA exposure
| Country | Overall | G551D/IVA patient group | F508del/SOC patient group |
|---|---|---|---|
| All countries, N | 209 | 72a | 137 |
| IVA exposure, mean (SD), months | NA | 21.8 (15.1) | NA |
| France, n (%) | 61 (29.2) | 10 (13.9) | 51 (37.2) |
| IVA exposure, mean (SD), months | NA | 15.9 (8.4) | NA |
| United Kingdom, n (%) | 54 (25.8) | 33 (45.8) | 21 (15.3) |
| IVA exposure, mean (SD), months | NA | 18.1b (11.4) | NA |
| Germany, n (%) | 47 (22.5) | 14 (19.4) | 33 (24.1) |
| IVA exposure, mean (SD), months | NA | 19.6 (9.6) | NA |
| Australia, n (%) | 38 (18.2) | 12 (16.7) | 26 (19.0) |
| IVA exposure, mean (SD), months | NA | 35.6 (24.1) | NA |
| Ireland, n (%) | 9 (4.3) | 3 (4.2) | 6 (4.4) |
| IVA exposure, mean (SD), months | NA | 30.0 (0.0) | NA |
IVA Ivacaftor, NA Not applicable, SD Standard deviation, SOC Standard of care
aDuration on ivacaftor exposure was missing for 6 patients
bn = 27